Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Enanta Pharmaceuticals, Inc.
< Previous
1
2
Next >
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
November 22, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
November 20, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
November 13, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
October 13, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
September 17, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
September 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Participate in Investor Conferences in September
August 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
August 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
July 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
June 20, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
June 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
May 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
May 09, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
May 08, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
May 08, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
May 02, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
April 25, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
April 17, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
April 06, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 05, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
March 14, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
March 08, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
February 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
January 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
January 06, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
November 22, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
November 21, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ENTA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.